Search | Clinical Trials Finder

Conditions: Aneurysmal Subarachnoid Hemorrhage
Interventions: Clazosentan, Placebo; Drug
Lead sponsor: Idorsia Pharmaceuticals Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 11
States / cities: Phoenix, Arizona • Englewood, Colorado • Boston, Massachusetts + 8 more

Conditions: Blood Loss
Interventions: Bipolar Sealer (Aquamantys), Standard of Care; Device · Procedure
Lead sponsor: Salient Surgical Technologies; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Chicago, Illinois • Royal Oak, Michigan

Conditions: Acquired Bleeding Disorder, Cardiac Surgery Requiring Cardiopulmonary Bypass
Interventions: activated recombinant human factor VII; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 18
States / cities: Birmingham, Alabama • Tucson, Arizona • San Francisco, California + 14 more

Conditions: Acute Coronary Syndrome, Myocardial Infarction, Coronary Artery Disease, Percutaneous Coronary Intervention
Interventions: CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin, Plavix (clopidogrel 75 mg) and aspirin; Drug
Lead sponsor: Cogentus Pharmaceuticals; Industry
Eligibility: 21 Years and older
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 247
States / cities: Alexander City, Alabama • Birmingham, Alabama • Geneva, Alabama + 205 more

Conditions: Dysfunctional Uterine Bleeding
Interventions: Medroxyprogesterone 17-Acetate; Drug
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Purpura, Thrombocytopenic, Idiopathic, Immune Thrombocytopenic Purpura
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Heavy Menstrual Bleeding, Uterine Fibroid
Interventions: Relugolix, Estradiol/norethindrone acetate, Relugolix placebo, Estradiol/norethindrone acetate placebo; Drug
Lead sponsor: Myovant Sciences GmbH; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 382 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 89
States / cities: Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 78 more

Conditions: Pelvic Hemorrhage
Interventions: Pelvic Angioembolization; Procedure
Lead sponsor: Methodist Health System; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Coronary Artery Disease
Interventions: Clopidogrel withdraw prior to CABG; Other
Lead sponsor: LifeBridge Health; Other
Eligibility: 18 Years to 85 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Tranexamic Acid, Cancer, Major Surgery
Interventions: Tranexamic Acid, Placebo; Drug · Other
Lead sponsor: Corewell Health West; Other
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 1
States / cities: Grand Rapids, Michigan

Conditions: Blood Loss, Surgical
Interventions: Volta tAN System, SHAM Volta tAN System; Device
Lead sponsor: University Surgical Vascular; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Watkinsville, Georgia

Conditions: Alzheimer's Disease
Interventions: No intervention; Other
Lead sponsor: Eisai Inc.; Industry
Eligibility: Not listed
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Nutley, New Jersey

Conditions: Tranexamic Acid Use, Blood Loss
Interventions: Not listed
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 576 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: ITP, Immune Thrombocytopenia
Interventions: Fostamatinib; Drug
Lead sponsor: Rigel Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 14
States / cities: Tamarac, Florida • Springfield, Illinois • Kansas City, Kansas + 10 more

Conditions: Fibroids
Interventions: Misoprostol, Placebo; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Seroma
Interventions: Microporous Polysaccharide Hemospheres (MPH); Device
Lead sponsor: Memorial Health University Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Savannah, Georgia

Conditions: Supratentorial Hemorrhage
Interventions: Aurora Surgiscope System; Device
Lead sponsor: Integra LifeSciences Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 20
States / cities: Burbank, California • Miami, Florida • Tampa, Florida + 17 more

Conditions: Uterine Fibroids, Endometriosis
Interventions: Relugolix Combination Tablet; Drug
Lead sponsor: Sumitomo Pharma Switzerland GmbH; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 120
States / cities: Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 98 more

Conditions: Bleeding, Implants, Breakthrough Bleeding
Interventions: Placebo, Curcumin; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 15 Years to 45 Years · Female only
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Severe Hemophilia A
Interventions: Factor VIII (rFVIIIFc), Advate®; Drug
Lead sponsor: Bioverativ Therapeutics Inc.; Industry
Eligibility: 12 Years and older · Male only
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 21
States / cities: Little Rock, Arkansas • Los Angeles, California • Orange, California + 17 more

Conditions: Primary Immune Thrombocytopenia
Interventions: Romiplostim, Predniso(lo)ne; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 3
States / cities: Long Beach, California • Peoria, Illinois • Fredericksburg, Virginia

Conditions: Hereditary Hemorrhagic Telangiectasia (HHT), Osler Weber Rendu Disease
Interventions: ATV-1601, Placebo; Drug
Lead sponsor: Atavistik Bio, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 6
States / cities: Phoenix, Arizona • Augusta, Georgia • Indianapolis, Indiana + 3 more

Conditions: Trauma, Hemorrhage, Coagulopathy
Interventions: Not listed
Lead sponsor: University of California, Los Angeles; Other
Eligibility: Not listed
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Thrombocytopenia, Hematologic Diseases, Bone Marrow Aplasia
Interventions: Thrombosomes; Biological
Lead sponsor: Cellphire Therapeutics, Inc.; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 6
States / cities: Duarte, California • Washington D.C., District of Columbia • Ann Arbor, Michigan + 3 more

Search by objective public record fields.

Clazosentan in Reducing Vasospasm-related Morbidity and All-cause Mortality in Adult Patients With Aneurysmal Subarachnoid Hemorrhage Treated by Surgical Clipping

Salient Aquamantys Spine Trial

Use of Activated Recombinant Human Factor VII in Cardiac Surgery

Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1)

Study of a Progestin to Prevent Bleeding Associated With Initiation of Medical Menopause With GnRH Agonist

An Epidemiological Study of Subjects With Immune Thrombocytopenic Purpura to Evaluate the Relationship Between Platelet Counts, Endogenous Thrombopoietin Levels, Endogenous Anti-Thrombopoietin Antibodies, and Selected Autoimmune Markers

LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Pelvic Angioembolization: A Prospective Multi-Institutional Study (Data From All Campuses Will be Used)

Time Based Strategy to Reduce Clopidogrel Associated Bleeding Related to Coronary Artery Bypass Graft (CABG)

TXA Study in Major Oncologic Surgery

Delivering Transcutaneous Auricular Neurostimulation to Reduce Blood Loss During Dialysis AV Graft Placement Procedures

A Retrospective Database Study for the Development and Validation of Algorithms for Intracerebral Hemorrhage and Seizures in Alzheimer's Disease

Tranexamic Acid Use and Blood Loss in Total Hip Arthroplasty

Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy

Misoprostol for Reduction of Blood Loss During Fibroid Surgery

The Effect of Arista on Post-Operative Bleeding and Wound Drainage Following Mastectomy

The MIRROR Registry: Minimally Invasive IntRaceRebral HemORrhage Evacuation

A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis

Use of Curcumin to Treat Unfavorable Bleeding Patterns in Contraceptive Implant Users

Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Subjects With Severe Hemophilia A

A Study of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Previously Untreated Primary Immune Thrombocytopenia (ITP)

Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT)

Transfusion Using Stored Whole Blood

Thrombosomes® in Bleeding Thrombocytopenic Patients